Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR
April 20, 2018
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official
April 19, 2018
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab
April 17, 2018
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey
April 17, 2018
- Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018
- Generic Drug Makers Required to Improve Package Inserts by Adding Information from Clinical Studies: MHLW Notification
April 17, 2018
- Xeljanz’s Ulcerative Colitis Use Up for MHLW Panel Review on April 27
April 16, 2018
- MHLW to Draft GL on Detailing Activities by Drug Reps as Early as Summer
April 13, 2018
- MHLW Compiles Drug Reuse Guide to Reduce Leftover Drug Solutions
April 13, 2018
- AZ’s PD-L1 Inhibitor Durvalumab Up for MHLW Panel Review on April 25
April 13, 2018
- MHLW to Issue Optimal Use Guidelines for Dupixent, Tecentriq
April 12, 2018
- MHLW Panel Starts Discussions on PMD Law Amendment; Will First Verify Results of Previous Amendment
April 12, 2018
- Chuikyo Holds 1st Listing Discussions since Overhaul, US Reference Prices Show Marked Declines after Rule Change
April 12, 2018
- Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
April 12, 2018
- MOF Calls for Using CEA to Make Reimbursement Decisions for Pricy Drugs
April 12, 2018
- Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
- Doctor Calls for Incentives for Effective, Lower-Cost Existing Drugs: LDP Taskforce
April 10, 2018
- MHLW Inks Memorandum of Cooperation with FDA Thailand
April 10, 2018
- MHLW to Launch New Public-Private Confab Focusing on Drug Pricing
April 10, 2018
- Mandatory Generic Use Tantamount to Treating Welfare Recipients in “Inferior” Manner: Lawmaker
April 6, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…